RANBAXY LABORATORIES - HEALTHY OUTLOOK
Article Abstract:
Ranbaxy Laboratories (RL) makes medicines. Its sales grew by 15 percent at Rs1,333.5 crore in 1997-98 (22 percent in 1996-97). Its net profit increased by 16 percent at Rs186.1 crore. Its exports grew by 14 percent at Rs593.50 crore. Its exports were hit by the fall in the prices of penicillin and penicillin products. The sale of dosage forms increased by 21 percent in 1997-98. RL introduced several new products in the cardio- vascular, central nervous and dermatology segments. It launched cefaclor and ranitidine formulations in USA. RL plans to grow through acquisitions. It acquired Crossland Labs and the Gufic brands. It plans to phase out the bulk drug manufacturing business, acquire more brands in Russia and South Africa and focus on the generics market. RL paid a dividend of 100 percent for 1997-98. (uh)
Publication Name: Dalal Street Journal
Subject: Business, international
ISSN:
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
DR REDDY'S LABORATORIES
Article Abstract:
The brands of Dr Reddy's Laboratories (DRL) were valued at Rs281 crore in March 1998. The company acquired brands like Styptovit, Styptomet, Styptochrome, Doxt and Trichodol from Dolphin Laboratories in December 1998. These brands are expected to add Rs25 crore to DRL's turnover in 1998-99. It has also received Rs15.15 crore towards intellectual property rights for two non- chemical entities that it had licenced to Novo Nordisk. DRL would have posted a net profit of Rs38 crore in the second quarter ended September 1998 but for the Rs10 crore made towards export receivables from CIS countries. (khr)
Comment:
The brands of Dr Reddy's Laboratories (DRL) were valued at Rs281 crore in March 1998.
Publication Name: Dalal Street Journal
Subject: Business, international
ISSN:
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
KREBS BIOCHEM: STRONG FUNDAMENTALS
Article Abstract:
Krebs Biochemicals Ltd has a near monopoly in the anti-asthmatic products sector. The company is trying to achieve US FDA approved standards in manufacturing. The US markets account for 90 percent of its exports while the rest goes to Canada, Hong Kong, Thailand, Ghana, and Japan. The company posted a net profit of Rs12.62 crore on sales of Rs34.78 crore in 1997-98. Its scrip is currently trading at Rs192.70. (khr)
Comment:
Posts a net profit of Rs12.62 crore on sales of Rs34.78 crore in 1997-98
Publication Name: Dalal Street Journal
Subject: Business, international
ISSN:
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: GUJARAT ALKALIES & CHEMICALS SIEL DEBENTURE RATINGS. MARDIA CHEMICALS ON THE LOOKOUT FOR JV PARTNER
- Abstracts: LUPIN LABORATORIES LTD DHARAMSI MORARJI CHEMICALS: CORE COMPETENCIES?
- Abstracts: Rx FOR SURVIVAL RANBAXY LABORATORIES AMONG WORLD's TOP 100 PHARMA COMPANIES KARNATAKA MALLADI STILL IN SICK BED
- Abstracts: KIRLOSKAR COMPUTER SERVICES LIMITED SATYAM COMPUTER SERVICES LTD. FORBES SETS UP INDIAN SUBSIDIARY
- Abstracts: IPCA LABORATORIES LIMITED BURROUGHS WELLCOME SALES UP. RECKITT PIRAMAL SETS Rs240 CRORE AS SALES TARGETS